176 related articles for article (PubMed ID: 29195926)
1. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
Hamilton CA; Miller A; Casablanca Y; Horowitz NS; Rungruang B; Krivak TC; Richard SD; Rodriguez N; Birrer MJ; Backes FJ; Geller MA; Quinn M; Goodheart MJ; Mutch DG; Kavanagh JJ; Maxwell GL; Bookman MA
Gynecol Oncol; 2018 Feb; 148(2):275-280. PubMed ID: 29195926
[TBL] [Abstract][Full Text] [Related]
2. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
Horowitz NS; Larry Maxwell G; Miller A; Hamilton CA; Rungruang B; Rodriguez N; Richard SD; Krivak TC; Fowler JM; Mutch DG; Van Le L; Lee RB; Argenta P; Bender D; Tewari KS; Gershenson D; Java JJ; Bookman MA
Gynecol Oncol; 2018 Jan; 148(1):49-55. PubMed ID: 29174555
[TBL] [Abstract][Full Text] [Related]
3. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
4. Who are the long-term survivors of high grade serous ovarian cancer?
Hoppenot C; Eckert MA; Tienda SM; Lengyel E
Gynecol Oncol; 2018 Jan; 148(1):204-212. PubMed ID: 29128106
[TBL] [Abstract][Full Text] [Related]
5. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
[TBL] [Abstract][Full Text] [Related]
6. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
8. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer.
Son JH; Kong TW; Paek J; Song KH; Chang SJ; Ryu HS
Int J Gynaecol Obstet; 2017 Dec; 139(3):352-357. PubMed ID: 28857180
[TBL] [Abstract][Full Text] [Related]
10. Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
Phippen NT; Secord AA; Wolf S; Samsa G; Davidson B; Abernethy AP; Cella D; Havrilesky LJ; Burger RA; Monk BJ; Leath CA
Gynecol Oncol; 2017 Oct; 147(1):98-103. PubMed ID: 28743369
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of ascites in epithelial ovarian cancer.
Huang H; Li YJ; Lan CY; Huang QD; Feng YL; Huang YW; Liu JH
Neoplasma; 2013; 60(5):546-52. PubMed ID: 23790174
[TBL] [Abstract][Full Text] [Related]
12. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
13. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
Kaern J; Aghmesheh M; Nesland JM; Danielsen HE; Sandstad B; Friedlander M; Tropé C
Int J Gynecol Cancer; 2005; 15(6):1014-22. PubMed ID: 16343177
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with cytoreducibility among women with ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K; Morgan A
Gynecol Oncol; 2004 Nov; 95(2):377-83. PubMed ID: 15491760
[TBL] [Abstract][Full Text] [Related]
17. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
[TBL] [Abstract][Full Text] [Related]
18. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
[TBL] [Abstract][Full Text] [Related]
19. The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer.
Ayhan A; Günakan E; Alyazıcı İ; Haberal N; Altundağ Ö; Dursun P
Arch Gynecol Obstet; 2017 Nov; 296(5):989-995. PubMed ID: 28875365
[TBL] [Abstract][Full Text] [Related]
20. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]